News

Telehealth transforms mental health care for Medicare patients, replacing in-person visits while increasing overall spending, according to recent research findings.

Experts predict shifts in U.S. healthcare for this year, focusing on affordability, consumer demands, mental health equity and the essential role of doulas.

The oral versions may set records in 2026, and glucagon-like peptide 1 (GLP-1) drugs will pick up even more momentum as medications for cardiovascular risk reduction as well as obesity, predict experts.

New guidelines from the Health Resources and Services Administration (HRSA) aim to reduce cost and access barriers for detecting human papillomavirus, which is preventable.

People taking glucagon-like peptide 1 (GLP-1) drugs were 36% less likely to develop colorectal cancer than those taking aspirin, according to a real-world, head-to-head study.

Transthyretin amyloid cardiomyopathy causes heart failure through protein buildup in heart muscle. Three FDA-approved disease-specific therapies are available, but high costs limit access.

Primary care must ensure that patients have access to the full spectrum of preventive tools, including nutrition services, to reduce chronic conditions and avoid their associated costs.

New research reveals how gastric cancer cells exploit WNT signaling for growth, revealing potential treatment targets to combat this deadly disease.

Universal recommendations dropped include vaccines for COVID-19 and flu shots.

Write-ups of presentations on the 340B Drug Pricing Program were among the most viewed conference-related articles on the MHE website in 2025.

The most-viewed articles from our print publication included our November 2025 cover story on AI and our April 2025 cover story on Medicaid cuts.

Lytenava, an ophthalmic bevacizumab formulation to treat patients with wet age-related macular degeneration, received yet another FDA complete response letter. The agency is asking for confirmatory efficacy data beyond existing NORSE trial results.

Lucille Accetta, RPh, M.P.H., MBA, of CVS Health, foresees more progress in the push for simplification. A.J. Loiacono of Judi Health and Capital Rx, predicts unified management of healthcare financing and benefits on one "healthcare operating system."

Predictions from Tracy Baroni Allmon, BS Pharm, Eva Borden, Sharon Faust, Mike Kolodij, and James Margiotta

The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients experiencing increased skin cancer risk, highlighting the need for vigilant monitoring and innovative treatment strategies.

Predictions from Marci Chodroff, M.D., Jeffrey Casberg, RPh, M.S., Sarah Emond, M.P.P., Adam Kautzner, Pharm.D., David Fields, Nate Karnitz, MBA, and David Blair

New studies from the year revealed connections between medications, environmental factors and innovative treatments for skin conditions including vitiligo and atopic dermatitis.

GLP-1 obesity drugs saw shifting coverage and access in 2025, with low long-term adherence, payer cost concerns, new generics and key regulatory and formulary moves shaping use.

In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising new and repurposed therapies for pulmonary fibrosis.

This year in type 1 diabetes, researchers advanced immune-reprogramming nanoparticle therapies and hypoimmune stem cell transplants, launched pivotal islet cell therapy trials, updated screening and treatment guidelines, and warned that cuts to research funding could slow future innovation.

Breakthrough treatments, shifting care models and persistent system challenges defined cancer care this year, from evidence that CAR T-cell therapy can lower costs and treatment burden in mantle cell lymphoma to promising off-the-shelf cancer vaccines.

This year, we explored how innovations in women's health are bridging care gaps, addressing biases and enhancing access to vital treatments and screenings.

Tylenol and autism, the Inflation Reduction Act, the One Big Beautiful Bill, Most Favored Nation pricing and direct drug sales to consumers were some of the biggest news items we covered in 2025.

Medicare price negotiations, higher costs driven by cancer and GLP-1 drugs and Medicare’s pilot program for obesity drugs are some of the biggest trends this year that will continue to impact managed care in 2026.

Transparency, prior authorization, PBM reform and PBM offered genomics testing are some the trends Formulary Watched tracked in 2025.

Discover groundbreaking treatments for prurigo nodularis, including vixarelimab and soficitinib, offering hope for effective symptom relief and improved quality of life.

The approval comes two months after Jascayd (nerandomilast) was approved for idiopathic pulmonary fibrosis.